L

Lipocine

D
LPCN
USD
-0.06
(-1.2097%)
Market Closed
414.00
Volume
0.02
EPS
-
Div Yield
-3.024691
P/E
26,204,906.00
Market Cap
Today
-1.2097%
1 Week
22.500%
1 Month
32.075%
6 Months
13.426%
12 Months
37.640%
Year To Date
75.627%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
AMRN
0.0012
(0.2027%)
USD
I
ICPT
(%)
USD
M
MNK
-0.0649
(-16.0683%)
USD
T
TEVA
-0.105
(-0.5876%)
USD
V
VKTX
3.72
(5.7692%)
USD
A
AEMD
0.0419
(11.7697%)
USD
C
CPRX
0.94
(4.6056%)
USD
M
MSB
0.79
(3.7441%)
USD
O
ONTX
(%)
USD

Title:
Lipocine

Sector:
Healthcare
Industry:
Biotechnology
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Do you need help or have a question?
Contact Us